




# Investor Fact Sheet

## Half-year 2021/22


(Unaudited Swiss GAAP FER figures)  
in thousand CHF

	Half-year 2021/22	in %	Half-year 2020/21	in %	Change	in %
<b>Sales of goods and services group</b>	<b>222588</b>	<b>100.0%</b>	199512	100.0%	23075	11.6%
Ypsomed Delivery Systems	118331	53.2%	108328	54.3%	10003	9.2%
Ypsomed Diabetes Care	95206	42.8%	84097	42.2%	11109	13.2%
Others	9050	4.1%	7087	3.6%	1963	27.7%
Gross profit	52342	23.5%	47497	23.8%	4845	10.2%
<b>Operating profit</b>	<b>10489</b>	<b>4.7%</b>	8521	4.3%	1968	23.1%
Financial income	1114	0.5%	3608	1.8%	-2495	-69.1%
Financial expenses	-3035	-1.4%	-4320	-2.2%	1285	-29.7%
Income taxes	-1443	-0.6%	-1154	-0.6%	-290	25.1%
<b>Net profit</b>	<b>7124</b>	<b>3.2%</b>	6655	3.3%	468	7.0%
<b>Earnings per share</b> in CHF	<b>0.56</b>		0.53		0.03	6.7%
Operating profit	10489	4.7%	8521	4.3%	1968	23.1%
Depreciation and impairment of fixed assets	18904		15698		3206	20.4%
Amortisation and impairment of intangible assets	13036		9793		3243	33.1%
<b>EBITDA</b> (operating profit before depreciation and amortisation)	<b>42429</b>	<b>19.1%</b>	34013	17.0%	8416	24.7%
Equity ratio in %	52.4%		53.5%		-1.1%	
Investments in fixed assets	24154		32085		-7932	-24.7%
Investments in intangible assets	26919		28586		-1667	-5.8%
Number of employees	1878		1816		62	3.4%
Number of full-time positions	1786		1727		59	3.4%

### Turnover at group level



### EBIT at group level



\* See Notes to the consolidated semiannual financial statements no 8, Restatement.

## my life Diabetes Care

With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed's subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).

### mylife™ product portfolio (selection)



## Delivery Systems

Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world's largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.

Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.

### YDS product portfolio (selection)



**Legal disclaimer:** The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.

### Ypsomed Holding AG

Thomas Kutt, Head Investor Relations // Brunnmattstrasse 6 // 3401 Burgdorf // +41 34 424 35 55 // [thomas.kutt@ypsomed.com](mailto:thomas.kutt@ypsomed.com) // [www.ypsomed.ch](http://www.ypsomed.ch)